Research programme: inhaled dry powder respiratory therapeutics - TFF Phartmaceuticals

Drug Profile

Research programme: inhaled dry powder respiratory therapeutics - TFF Phartmaceuticals

Latest Information Update: 25 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TFF Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Respiratory tract disorders

Most Recent Events

  • 11 Jul 2018 TFF Pharmaceuticals receives patent allowance for ''compositions and methods of making brittle-matrix particles through blister pack freezing'' in USA
  • 03 Apr 2018 The Thin Freezing Film technology has a combination of 30 patents and patent pending applications
  • 03 Apr 2018 TFF Pharmaceuticals in-licenses Thin Film Freezing platform technology from the University of Texas at Austin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top